|Date:||Wednesday, February 13, 2013|
|Time:||5:00 p.m. ET|
|Telephone Access:||Domestic callers, dial 877-674-2415; reference the Dyax conference call|
|International callers, dial 708-290-1364|
|No passcode required.|
|Online Access:||Go to the Investor Relations section of the Dyax website( www.dyax.com) and follow instructions for accessing the livewebcast. Participants may register in advance.|
The Company is currently developing products to expand its angioedema portfolio, including diagnostic strategies to identify plasma kallikrein (bradykinin) mediated (PKM) angioedema and a therapeutic candidate, DX-2930, for the prophylactic treatment of, HAE and other PKM angioedemas.KALBITOR and DX-2930 were identified using Dyax’s patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 12 royalty and/or milestone bearing product candidates in various stages of clinical development, including three in Phase 3 trials. Dyax is headquartered in Burlington, Massachusetts. For additional information about Dyax, please visit www.dyax.com.